Creation of Novel Cell-Penetrating Peptides for Intracellular Drug Delivery Using Systematic Phage Display Technology Originated from Tat Transduction Domain(Biochemistry)
スポンサーリンク
概要
- 論文の詳細を見る
Many biologically active proteins need to be delivered intracellularly to exert their therapeutic action inside the cytoplasm. Cell penetrating peptides (CPPs) have been developed to efficiently deliver a wide variety of cargo in a fully biological active form into a range of cell types for the treatment of multiple preclinical disease models. To further develop this methodology, we established a systematic approach to identify novel CPPs using phage display technology. Firstly, we screened a phage peptide library for peptides that bound to the cell membrane. Secondly, to assess functionality as intracellular carriers, we recombined cDNAs of binding peptides with protein synthesis inhibitory factor (PSIF) to create fusion proteins. Randomly chosen clones were cultured and expression of peptide-PSIF fusion proteins induced, followed by screening of protein synthesis activity in cells. Using this systematic approach, novel and effective CPPs were rapidly identified. We suggest that these novel cell-penetrating peptides can utilized as drug delivery tools for protein therapy or an analytical tool to study mechanisms of protein transduction into the cytoplasm.
- 社団法人日本薬学会の論文
- 2007-02-01
著者
-
Nagano Kazuya
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation (NiBio)
-
Abe Yasuhiro
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation (NiBio)
-
Kamada Haruhiko
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation (NiBio)
-
Nakagawa Shinsaku
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka Univ
-
Kiwada Hiroshi
徳島大学 ヘルスバイオサイエンス研究部薬物動態制御学
-
Kiwada Hiroshi
Faculty Of Pharmaceutifal Sciences The University Of Tokushima
-
提 康央
Faculty Of Pharmaceutical Sciences Osaka University
-
真弓 忠範
Graduate School Of Pharmaceutical Sciences Kobe-gakuin Univ.
-
真弓 忠範
大阪大学 薬 薬剤
-
OKAMOTO Takayuki
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University
-
KAWAMURA Maki
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
SHIBATA Hiroko
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
OHKAWA Akiko
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
NOMURA Tetsuya
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
SATO Masaki
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
MUKAI Yohei
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
SUGITA Toshiki
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
IMAI Sunao
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
TSUTSUMI Yasuo
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
MAYUMI Tadanori
Department of Cell Therapeutics, Graduate School of Pharmaceutical Sciences, Kobe Gakuin University
-
TSUNODA Shin-ichi
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
村上 智彦
神戸学院大学 薬
-
Nomura Tetsuya
Graduate School Of Pharmaceutical Sciences Osaka University
-
Nomura Tetsuya
Graduate School Of Pharmaceutical Sciences Kumamoto University
-
Tsunoda S
Lab. Of Pharmaceutical Proteomics National Inst. Of Biomedical Innovation (nibio)
-
Shibata Hiroko
Laboratory Of Pharmaceutical Proteomics National Institute Of Biomedical Innovation (nibio)
-
Shibata Hiroko
医薬基盤研究所 創薬プロテオミクスプロジェクト
-
Nakagawa S
Graduate School Of Pharmaceutical Sciences Osaka University
-
Nakagawa S
Osaka Univ. Osaka Jpn
-
Nakagawa Shinsaku
中華人民共和国
-
Mukai Yohei
Graduate School Of Pharmaceutical Sciences Osaka University
-
Mukai Yohei
医薬基盤研究所 創薬プロテオミクスプロジェクト
-
Higashisaka Kazuma
Dep. Of Toxicology And Safety Sci. Graduate School Of Pharmaceutical Sciences Osaka Univ.
-
Kamada Haruhiko
医薬基盤研究所 創薬プロテオミクスプロジェクト
-
Kamada Haruhiko
Laboratory Of Pharmaceutical Proteomics (lpp) National Institute Of Biomedical Innovation (nibio)
-
Abe Yasuhiro
Lab. Of Pharmaceutical Proteomics National Inst. Of Biomedical Innovation (nibio)
-
Abe Yasuhiro
医薬基盤研究所 創薬プロテオミクスプロジェクト
-
Imai Sunao
医薬基盤研究所 創薬プロテオミクスプロジェクト
-
Imai Sunao
Laboratory Of Pharmaceutical Proteomics National Institute Of Biomedical Innovation:department Of Bi
-
Nagano Kazuya
Lab. Of Pharmaceutical Proteomics National Inst. Of Biomedical Innovation (nibio)
-
Nagano Kazuya
医薬基盤研究所 創薬プロテオミクスプロジェクト
-
Sugita Toshiki
Lab. Of Pharmaceutical Proteomics National Inst. Of Biomedical Innovation
-
Sugita Toshiki
医薬基盤研究所 創薬プロテオミクスプロジェクト
-
Sugita Toshiki
Department Of Biopharmaceutics Graduate School Of Pharmaceutical Sciences Osaka University
-
Tsutsumi Y
Dep. Of Toxicology And Safety Sci. Graduate School Of Pharmaceutical Sciences Osaka Univ.
-
Kiwada Hiroshi
Department Of Pharmacokinetics And Biopharmaceutics Faculty Of Pharmaceutical Sciences The Universit
-
Imazu Susumu
Department Of Biopharmaceutics Graduate School Of Pharmaceutical Sciences Osaka University
-
Imazu Susumu
大阪大学 薬学研究科薬剤学
-
Tsujino Masaki
大阪大学 薬学研究科薬剤学
-
Morishita Yuki
Dep. Of Toxicology And Safety Sci. Graduate School Of Pharmaceutical Sciences Osaka Univ.
-
Morishita Yuki
大阪大学 薬学研究科毒性学
-
Kamiya Hiroyuki
Lab. For Molecular Design Of Pharmaceutics Fac. Of Pharmaceutical Sciences Hokkaido Univ.
-
Sato Masao
Department Of Legal Medicine Fukushima Medical University School Of Medicine
-
Sato Masao
Laboratory Of Pharmaceutical Proteomics National Institute Of Biomedical Innovation:department Of Bi
-
Kamada H
Yamagata Technopolis Foundation Yamagata Jpn
-
Kamada Hitoshi
Institute For Life Support Technology Yamagata Promotional Organization For Industrial Technology
-
Tsunoda Saburo
Divisions Of Medical Oncology Tochigi Cancer Center
-
Mayumi Tadanori
Faculty Of Pharmacy Osaka University
-
Mayumi Tadanori
Dep. Of Biopharmaceutics Grad. Sch. Of Pharm. Sci. Osaka Univ.
-
Mayumi Tadanori
Department Of Biopharmaceutics Graduate School Of Pharmaceutical Science Osaka University
-
Shibata Hiroshi
Laboratory For Health Care Science Research Center Suntory Ltd.
-
Nakagawa Shinsaku
Dep. Of Biotechnology And Therapeutics Graduate School Of Pharmaceutical Sciences Osaka Univ.
-
Nakagawa Shinsaku
Department Of Biopharmaceutics Graduate School Of Pharmaceutical Sciences Osaka University
-
Shibata H
Laboratory For Health Care Science Research Center Suntory Ltd.
-
堤 康央
医薬基盤研究所:大阪大学大学院薬学研究科:大阪大学臨床医工学融合研究教育センター
-
Sato M
Department Of Legal Medicine Fukushima Medical University School Of Medicine
-
Kamada H
Institute For Life Support Technology Yamagata Promotional Organization For Industrial Technology
-
Kiwada H
Faculty Of Pharmaceutifal Sciences The University Of Tokushima
-
Okamoto Tatsuyuki
Department Of Biopharmaceutics Graduate School Of Pharmaceutical Sciences Osaka University:departmen
-
Mayumi Tadanori
Faculty Of Pharmaceutical Sciences Kobe-gakuin University:faculty Of Pharmaceutical Sciences Osaka U
-
Tsutsumi Yasuo
Dep. Of Biopharmaceutics Grad. Sch. Of Pharm. Sci. Osaka Univ.
-
Momose T
大阪大学薬学部
-
Kawamura Maki
Laboratory Of Pharmaceutical Proteomics National Institute Of Biomedical Innovation:department Of Bi
-
Okamoto T
Department Of Biopharmaceutics Graduate School Of Pharmaceutical Sciences Osaka University:departmen
-
Ohkawa Akiko
Laboratory Of Pharmaceutical Proteomics National Institute Of Biomedical Innovation:department Of Bi
-
Kiwada Hiroshi
Department Of Pharmacokinetics And Biopharmaceutics Subdivision Of Biopharmaceutical Science Institu
-
Saito Hiroyuki
Third Department Of Internal Medicine Asahikawa Medical College
-
Shibata Hiroshi
Institute Of Health Care Science Suntory Wellness Limited
-
Nakagawa Shinsaku
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University
-
Abe Yasuhiro
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
-
Sugita Toshiki
Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation (NiBio)
-
Mukai Yohei
Laboratory of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University
-
Nagano Kazuya
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation
関連論文
- Transgene expression efficiency from plasmid DNA delivered as a complex with histone H3
- Urban Aerosols Induce Pro-inflammatory Cytokine Production in Macrophages and Cause Airway Inflammation in Vivo
- Optimized PEGylated Adenovirus Vector Reduces the Anti-vector Humoral Immune Response against Adenovirus and Induces a Therapeutic Effect against Metastatic Lung Cancer
- Amino Acids and Peptides. XXVI. Laminin-Related Peptide Poly (Ethylene Glycol) Hybrids and Their Inhibitory Effect on Experimental Metastasis
- Amino Acids and Peptides. XXV. Preparation of Fibronectin-Related Peptide Poly(ethylene glycol) Hybrids and Their Inhibitory Effect on Experimental Metastasis
- TNF-αの多様な in vivo 生理作用の中から, 目的とする抗腫瘍作用と副作用を分離し得る Bioconjugation 設計の確立
- In Vitro and In Vivo Tumor Suppressive Activity Induced by Human Telomerase Transcriptase-Targeting Antisense Oligonucleotides Mediated by Cationic Liposomes(CELL AND TISSUE ENGINEERING)
- Cell-Penetrating Peptides as Adenovirus Vector Carrier
- Creation of Novel Cell-Penetrating Peptides for Intracellular Drug Delivery Using Systematic Phage Display Technology Originated from Tat Transduction Domain(Biochemistry)
- Non-Methylated CpG Motif Packaged into Fusogenic Liposomes Enhance Antigen-Specific Immunity in Mice(Highlighted paper selected by Editor-in-chief,Pharmacology)
- Vaccine Efficacy of Fusogenic Liposomes Containing Tumor Cell-Lysate against Murine B16BL6 Melanoma(Pharmacology)
- Anti-tumor Responses Induced by Chemokine CCL19 Transfected into an Ovarian Carcinoma Model via Fiber-Mutant Adenovirus Vector(Biopharmacy)
- Fusogenic Liposome can be Used as an Effective Vaccine Carrier for Peptide Vaccination to Induce Cytotoxic T Lymphocyte (CTL) Response(Biopharmacy)
- プロテオーム創薬にかなう機能性人工蛋白質の迅速創出とそのPEGylationへの展開 (化学と生物学の接点がつくるNewバイオテクノロジー) -- (蛋白質の修飾をコントロールする)
- 蛋白療法の最適化にかなうあらたな薬物送達戦略 (ナノテクノロジー創薬--DDSの新展開)
- ファージ表面提示法を駆使した機能性人工蛋白質の創出とDDSへの展開
- Lactoferrin Inhibits Platelet Production from Human Megakaryocytes in Vitro(Molecular and Cell Biology)
- My Technology 医薬価値に優れた機能性人工タンパク質の網羅的かつ迅速同定システムとプロテオーム創薬への展開
- P-130 都市大気粉塵の免疫毒性メカニズムに関する基礎的検討(ポスターセッション)
- P-064 非結晶性ナノシリカの物性と有害性発現との連関評価(2)(ポスターセッション)
- P-063 非結晶性ナノシリカの物性と有害性発現との連関評価(1)(ポスターセッション)
- P-062 非結晶性ナノシリカの遺伝毒性に関する基礎的検討(ポスターセッション)
- P-060 / O-06 カーボンナノチューブの変異原性に関する基礎的検討(ポスターセッション)
- 癌組織血管内皮細胞を標的としたミサイル療法の開発
- 生理活性ペプチドの高分子ハイブリッド化 DDS - ポリスチレンマレイン酸によるラミニン関連細胞接着ペプチドのバイオコンジュゲーションとその癌転移抑制効果 -
- 水溶性高分子の動態特性評価に基づいたバイオコンジュゲート医薬品の分子設計理論の構築
- ケモカイン及びサイトカイン発現アデノウイルスベクターの併用による癌遺伝子治療の最適化
- インテグリン指向性ファイバーミュータントアデノウイルスベクターの改良とその評価
- Fast Binding Kinetics and Conserved 3D Structure Underlie the Antagonistic Activity of Mutant TNF : Useful Information for Designing Artificial Proteo-Antagonists
- Creation of Novel Protein Transduction Domain (PTD) Mutants by a Phage Display-Based High-Throughput Screening System(Biochemistry)
- Quality Enhancement of the Non-immune Phage scFv Library to Isolate Effective Antibodies(Highlighted paper selected by Editor-in-chief,Biochemistry)
- 目的とする生理活性を完全に保持した機能性変異蛋白質の迅速構築とそのDDSへの応用
- ファージディスプレイシステムを利用した部位特異的PEGylation
- 癌抗原WT1標的癌ワクチン療法に向けた抗原デリバリーデバイス
- 腎指向性修飾高分子の特性評価
- 液性免疫隔離能を有する細胞性製剤の設計
- リポソームのカチオン化による腫瘍ワクチン用アジュバント効果増強
- Development of new anti-TNF therapy
- Development of Novel Drug Delivery System (DDS) Technologies for Proteomic-Based Drug Development
- Selective Enhancer of Tumor Vascular Permeability for Optimization of Cancer Chemotherapy (Pharmacognosy)
- Effective Cancer Targeting Using an Anti-tumor Tissue Vascular Endotheliumm specific Monoclonal Antibody (TES-23)
- 経鼻薬物キャリアーとしての膜融合リポソームの機能評価と経鼻ワクチンへの応用
- リポソームの陽電荷密度上昇による腫瘍ワクチン用アジュバント効果増強
- MITO-Porter : a liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion
- Establishment of Evaluation Method for siRNA Delivery Using Stable Cell Line Carrying the Luciferase Reporter Gene(Molecular and Cell Biology)
- In Vitro Efficacy of a Sterically Stabilized Immunoliposomes Targeted to Membrane Type 1 Matrix Metalloproteinase (MT1-MMP)(Biopharmacy)
- Neutralizing Antibody Evasion Ability of Adenovirus Vector Induced by the Bioconjugation of Methoxypolyethylene Glycol Succinimidyl Propionate(MPEG-SPA)(Biopharmacy)
- Anti-angiogenic Effects of Dimethyl Sulfoxide on Endothelial Cells(Pharmacognosy)
- 細胞内薬物動態制御を目指した機能性ナノ粒子の細胞質内導入(DDSとナノ粒子)
- Preparation and Biological Activities of a Bivalent Poly(Ethylene Glycol) Hybrid Containing an Active Site and Its Synergistic Site of Fibronectin
- 次世代DDS製剤としての綱胞内徐放化システムの開発
- Tumor Necrosis Factor α-Gene Therapy for an Established Murine Melanoma Using RGD (Arg-Gly-Asp) Fiber-mutant Adenovirus Vectors
- グルコースセンサー機能を有する細胞性製剤の糖尿病治療への可能性
- Complex Formation with Plasmid DNA Increases the Cytotoxicity of Cationic Liposomes(Biopharmacy)
- Gene Expression in Primary Cultured Mouse Hepatocytes with a Cationic Liposomal Vector, TFL-3 : Comparison with Rat Hepatocytes(Biopharmacy)
- Culture Time-Dependent Gene Expression in Isolated Primary Cultured Rat Hepatocytes by Transfection with the Cationic Liposomal Vector TFL-3
- Effect of Cationic Liposomes in an in Vitro Transcription and Translation System
- An infantile/juvenile form of Alexander disease caused by a R79H mutation in GFAP
- 3P-081 ファージ表面提示法を用いたTNFR1指向性リンフォトキシンαの創製とその特性評価(蛋白質工学,進化工学,第46回日本生物物理学会年会)
- Cell Deliveryによる癌治療法の開発 : 新規ケモカインILCのin vivoにおける細胞遊走能評価と癌治療への応用
- ファイバーミュータントアデノウイルスベクターによる樹状細胞への遺伝子導入効率と機能修飾
- 癌サイトカイン遺伝子治療における次世代型ファイバーミュータントアデノウイルスベクターの有用性
- ケモカインを用いた癌免疫療法の基礎的検討
- D-10 ラミニンα鎖のN末端ドメインVIの生物活性部位の同定
- Amino Acids and Peptides.XXXVIII.Facile Synthesis of Laminin-Related Peptide-Poly(Ethylene Glycol)Hybrids by the Solid Phase Method
- Arsenic Trioxide Inhibits Human T Cell-Lymphotropic Virus-1-Induced Syncytiums by Down-Regulating gp46
- DNA Microarray Analysis of Whole Blood Cells and Insulin-Sensitive Tissues Reveals the Usefulness of Blood RNA Profiling as a Source of Markers for Predicting Type 2 Diabetes
- DNA Microarray Analysis of Type 2 Diabetes-Related Genes Co-regulated between White Blood Cells and Livers of Diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) Rats
- 膜融合リポソームを用いた細胞質内薬物徐放化システムの開発に関する研究(第1報) : ナノスフェアーの細胞質内導入法の確立
- Characterization of Bovine Serum Factor Triggering the Lysis of Liposomes via Complement Activation
- Effect of Serum Components from Different Species on Destabilizing Hydrogenated Phosphatidylcholine-Based Liposomes
- Calpain 10 as a Predictive Gene for Type 2 Diabetes : Evidence from a Novel Screening System Using White Blood Cells of Otsuka Long-Evans Tokushima Fatty (OLETF) Rats (Biopharmacy)
- Conjugation of a Laminin-Related Antimetastatic Peptide with Chitosan (Part 3)
- Growth Inhibition of Human Leukemia HL-60 Cells by an Antisense Phosphodiester Oligonucleotide Encapsulated into Fusogenic Liposomes
- A Bivalent Poly (ethylene glycol) Hybrid Containing an Active Site (RGD) and a Synergistic Site of Fibronectin
- Regioselective Conjugation of Chitosan with a Laminin-related Peptide, Tyr-Ile-Gly-Ser-Arg, and Evaluation of Its Inhibitory Effect on Experimental Cancer Metastasis
- Genome Wide Expression Analysis of White Blood Cells and Liver of Pre-diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) Rats Using a cDNA Microarray
- Species Difference in Correlation between in Vivo/in Vitro Liposome-Complement Interactions
- In Vivo Studies on the Role of Complement in the Clearance of Liposomes in Rats and Guinea Pigs
- Cell cycle dependent transcription, a determinant factor of heterogeneity in cationic lipid-mediated transgene expression.
- Gene Expression Analysis during Platelet-Like Particle Production in Phorbol Myristate Acetate-Treated MEG-01 Cells(Molecular and Cell Biology)
- In vivo Anti-tumor Efficacy of Polyethylene Glycol-modified Tumor Necrosis Factor-α against Tumor Necrosis Factor-resistant Tumors
- Preferential Activity of Wild-type and Mutant Tumor Necrosis Factor-α against Tumor-derived Endothelial-like Cells
- Preparation of Laminin γ1 Chain Related Peptide Poly (Ethylene Glycol) Hybrid
- Effect of Additives on Dissolution and Swelling of Soybean Lecithin Microcapsules Prepared Using the Wurster Process
- Phase Separation in Microcapsule Membranes Composed of Soybean Lecithin, Cholesterol, Stearic Acid and Polyvinylpyrrolidone
- Increased Gene Expression by Cationic Liposomes (TFL-3) in Lung Metastases Following Intravenous Injection(Biopharmacy)
- Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid
- Mitochondrial drug delivery and mitochondrial disease therapy--an approach to liposome-based delivery targeted to mitochondria.
- ファージ表面提示法を駆使した機能性人工蛋白質の創出とDDSへの展開
- Modifying the antigen-immunization schedule improves the variety of monoclonal antibodies obtained from immune-phage antibody libraries against HIV-1 Nef and Vif(MEDICAL BIOTECHNOLOGY)
- Safety Evaluation Study of Nanomaterials Aimed at Promoting Their Acceptance by Society
- 遺伝子治療におけるDDS
- 新規タンパク療法としての粘膜ワクチン : 経鼻ワクチンキャリアーとしての膜融合リポソームの応用
- 粘膜ワクチンの新しい展開 (〔2001年10月〕第1土曜特集 粘膜免疫の分子機構とその破綻) -- (粘膜免疫の特殊性を応用した新しい治療法)
- 腫瘍血管を標的とした癌治療法の開発
- 膜融合リポソームを用いた細胞内への遺伝子デリバリーと遺伝子発現効率の改善
- Mitochondrial delivery of mastoparan with transferrin liposomes equipped with a pH-sensitive fusogenic peptide for selective cancer therapy.
- ラミニン由来ガン転移抑制ペプチドとキトサンとのハイブリッド体の調製
- In Vitro and In Vivo Tumor Suppressive Activity Induced by Human Telomerase Transcriptase-Targeting Antisense Oligonucleotides Mediated by Cationic Liposomes